Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc upbeat on heart drug, cancer vaccine despite setbacks - Reuters


Wednesday, 5 Feb 2014 12:04pm EST 

Glaxosmithkline Plc:Two high-risk bets by GlaxoSmithKline Plc on new ways to fight heart disease and cancer were dealt a double blow last year by dud clinical trials - but the company remains hopeful about both projects - Reuters.Chief Executive Andrew Witty said there were still intriguing opportunities for its heart drug darapladib and MAGE-A3 therapeutic cancer vaccine.Many analysts stripped out forecasts for darapladib, which is designed to prevent heart attacks and strokes in a completely different way from cholesterol-lowering drugs, after it failed to reduce risks in the first of two big final Phase III trials in Nov.GSK, however, is continuing to investigate the drug's role in coronary heart disease and Witty told analysts in a call following full-year results that further data on the approach would be presented at a medical meeting next month.He was also upbeat about prospects for the MAGE-A3 cancer vaccine in other tumour settings, despite initial negative results in melanoma in Sept.Unlike traditional preventative vaccines, MAGE-A3 is designed for people with established disease, helping their immune systems to prevent the return of tumours after surgery.He also highlighted a new triple combination respiratory drug, a long-acting integrase inhibitor for HIV and a drug for pre-term labour, all of which could start final Phase III clinical testing this year or next. 

Company Quote

1392.0
13.5 +0.98%
19 Dec 2014